Biogen Idec Stock Spikes Following Second Quarter Earnings Beat

Updated with new information, stock price.

NEW YORK (TheStreet) -- Biogen Idec (BIIB) shares are up 10% to $335 Wednesday after the biotech company reported a year-over-year 40% second quarter increase in revenues to $2.4 billion, beating analysts' $2.2 billion consensus estimate. The company also raised financial guidance for the remainder of 2014.

Earnings for the quarter were $3.49 per diluted share, well ahead of analysts' expectations of $2.83 per share. The company's outsized profits were driven by better than expected sales of the multiple sclerosis drugs Tecfidera and strong Avonex sales. Tecfideral sales totaled $700 million worldwide, trouncing the consensus estimate of $558 million. On its conference call, Biogen executives said Tecfidera's launch in Europe was stronger than it had anticipated. especially in Germany, which accounted for nearly 75% of the $115 million in overseas sales.

Biogen raised its full year guidance, increasing total revenue growth expectations to between 38% and 41%, up from its own previous estimates of between 26% and 28% growth, as well as Wall Street's consensus estimate of 28% growth.

On its call, Biogen said top-line results from a phase II study of its anti-LINGO antibody in optic neuritis would be announced in January 2015 -- a slight delay to expectations for data at the end of 2014. The anti-LINGO antibody is perhaps the most important product in Biogen's research pipeline because of its potential to reverse chronic neuro-degenerative diseases like multiple sclerosis. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.


BIIB CharttBIIB data by YCharts


STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home